Showing 37–48 of 192 resultsSorted by latest
Pharma & Biotech
Orenitram, revenues touched $120.7mn in Q1FY25, representing a growth of 13.7% from $106.2mn in Q1FY24 and Remodulin, contributed a 8% increase in revenues from $128mn in Q1FY24 to $138.2mn in Q1FY25, this shows that the overall portfolio of UTHR has a solid balance across its product line.
Regeneron’s primary growth driver for future growth has to be it’s investments in strong R&D. Regeneron plans to invest $5bn into R&D in 2025.
Edward Lifesciences has reported a strong Q1 revenue growth with sales touching $1.41bn which is a 6.2% increase compared to previous year of the same period.
CVS posted a strong Q1 performance, revenues reaching $94.6bn making it a 7% growth in revenues from Q1FY24. The adjusted EPS grew from $1.31 in Q1FY24 to $2.25 in Q1FY25.
Biogen’s newly launched drugs i.e. LEQEMBI, ZURZUVAE, SKYCLARYS, and QALSODY collectively generated close to ~$200mn in revenue in Q1 FY25.
Entresto, which is an oral, first-in-class angiotensin receptor-neprilysin inhibitor. Sales of Entresto was $2.3bn up by 50% when compared to Q1FY24.
AMGN has posted double digit sales growth with 14 products mainly with their blockbuster drugs such as Repatha, Evenity and Prolia. Other products also saw a significant growth in sales.
AbbVie is seeing strong progress in its pipeline with new drugs that could support future growth.
AZN secured 13 approvals across key regions and announced five positive Phase III results, including two NMEs.
PFE has maintained its 2025 financial guidance, excluding the potential impact of future trade and tariff policy changes.
Novo showed strong results in Q1FY25, with 18% growth in sales and 20% growth in operating profit
In the MPT segment, sales rose 6% to $1.3bn. Infusion Therapies grew due to strong US demand, and Nutrition sales improved thanks to better supply.